SCHEMBL24920867

SCHEMBL24920867

COc1cnnc(-c2nc(C)no2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.37
MAPT P10636 3/20 0.36
POLB P06746 1/20 0.36
ACHE P22303 1/20 0.36
PTGDR Q13258 1/20 0.35
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TP53 P04637 2/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CG P48736 1/20 0.34
PDE10A Q9Y233 1/20 0.34
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24920812 0.75 MAPT (0.44) MAPTRAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL17109385 0.75 CCR1 (0.58) CNR2MAPTACHERAB9ANPC1
SCHEMBL24920833 0.74 PTGDR (0.41) MAPTPTGDRRAB9ANPC1SMN1; SMN2
SCHEMBL24920815 0.73 CCR1 (0.34) PDE10A
SCHEMBL17109362 0.73 PDE10A (0.46) CNR2MAPTACHEPTGDRRAB9A
SCHEMBL24921159 0.73 GABRA5 (0.45) MAPTACHERAB9ANPC1SMN1; SMN2
SCHEMBL24921191 0.73 RAB9A (0.48) MAPTACHERAB9ANPC1SMN1; SMN2
SCHEMBL24920835 0.72 NOTUM (0.51) MAPTKMT2AHPGD
SCHEMBL10094731 0.71 RAB9A (0.61) MAPTACHERAB9ANPC1SMN1; SMN2
SCHEMBL24921535 0.71 OPRK1 (0.39) MAPTRAB9ANPC1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed